US 11,883,391 B2
Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies
James Campbell, San Jose, CA (US); Israel Charo, Mountain View, CA (US); Thomas Schall, Mountain View, CA (US); Rajinder Singh, Belmont, CA (US); Yibin Zeng, Foster City, CA (US); and Penglie Zhang, Foster City, CA (US)
Assigned to CHEMOCENTRYX, INC., Thousand Oaks, CA (US)
Filed by ChemoCentryx, Inc., Mountain View, CA (US)
Filed on Mar. 31, 2021, as Appl. No. 17/219,172.
Claims priority of provisional application 63/002,747, filed on Mar. 31, 2020.
Prior Publication US 2021/0308119 A1, Oct. 7, 2021
Int. Cl. A61K 31/4709 (2006.01); C07K 16/24 (2006.01); A61P 1/00 (2006.01); A61K 31/4402 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/4709 (2013.01) [A61K 31/4402 (2013.01); A61P 1/00 (2018.01); C07K 16/244 (2013.01); C07K 16/2866 (2013.01)] 8 Claims
 
1. A method of treating or reducing the development of inflammatory bowel disease in a mammal, said method comprising administering a suitable amount of a CCR9 inhibitor with an anti-IL-23 or anti-IL-23 receptor blocking antibody,
wherein the CCR9 inhibitor is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.